AAA
VYGR icon

Affinity Asset Advisors’s Voyager Therapeutics VYGR Stock Holding History

Affinity Asset Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-51,727
Closed -$303K – 103
2024
Q3 		$303K Buy
+51,727
New +$376K 0.04% 81

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Affinity Asset Advisors's VYGR Position: Q4 2024 in Review

Affinity Asset Advisors sold out of Voyager Therapeutics (VYGR) in Q4 2024, closing a stake of 51,727 shares — an estimated $303K sold.

Affinity Asset Advisors first reported a position in VYGR in Q3 2024 and held it in 1 quarter. The position peaked at $303K in Q3 2024. 132 funds tracked by Wall St. Rank hold VYGR as of Q4 2024.

  • Affinity Asset Advisors reported no remaining Voyager Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 51,727 Voyager Therapeutics shares in Q4 2024, an estimated $303K.
  • Affinity Asset Advisors first reported a position in Voyager Therapeutics in Q3 2024 and held it in 1 quarter.
  • Affinity Asset Advisors's Voyager Therapeutics position peaked at $303K in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2024.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.